Corona Remedies Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Corona Remedies Ltd is ₹ 1580 as of 19 Feb 10:41 . The P/E Ratio of Corona Remedies Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the decline of -100% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the decline of -100% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Corona Remedies Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Corona Remedies Ltd or Syncom Formulations (India) Ltd?

Market cap of Corona Remedies Ltd is 10,722 Cr while Market cap of Syncom Formulations (India) Ltd is 1,353 Cr

What are the key factors driving the stock performance of Corona Remedies Ltd and Syncom Formulations (India) Ltd?

The stock performance of Corona Remedies Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Corona Remedies Ltd and Syncom Formulations (India) Ltd?

As of May 12, 2026, the Corona Remedies Ltd stock price is INR ₹1753.2. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.4.

How do dividend payouts of Corona Remedies Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Corona Remedies Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.